Statins use and COVID-19 outcomes in hospitalized patients.
Statins use and COVID-19 outcomes in hospitalized patients.
复制标题
DOI：
10.1371/journal.pone.0256899
复制
发表时间：
2021
期刊：
影响因子：
3.7
通讯作者：
Karakousis PC
中科院分区：
文献类型：
--
作者：
Ayeh SK;Abbey EJ;Khalifa BAA;Nudotor RD;Osei AD;Chidambaram V;Osuji N;Khan S;Salia EL;Oduwole MO;Yusuf HE;Lasisi O;Nosakhare E;Karakousis PC
迫切需要新的治疗策略来逆转COVID-19相关的肺部炎症。最近的证据表明，降胆固醇药物，他汀类药物，与各种呼吸道感染患者的死亡率降低。我们试图调查住院患者使用他汀类药物与COVID-19疾病严重程度之间的关系。对2020年3月1日至2020年6月30日期间在约翰霍普金斯医疗机构住院的COVID-19患者进行了回顾性分析。关注的结局是死亡率和严重COVID-19感染，定义为住院时间延长（≥ 7天）和/或有创机械通气。Logistic回归、考克斯比例风险回归和倾向评分匹配用于获得协变量和结局之间的单变量和多变量关联以及他汀类药物使用的平均治疗效果。在符合我们入选标准的4,447例患者中，594例（13.4%）患者在入院时暴露于他汀类药物，其中340例（57.2%）为男性。他汀类药物使用者的平均年龄高于非使用者[64.9 ± 13.4 vs. 45.5 ± 16.6岁，p <0.001]。使用他汀类药物对COVID-19相关死亡率的平均治疗效果为RR = 1.00（95%CI：0.99-1.01，p = 0.928），而对严重COVID-19感染的影响为RR = 1.18（95%CI：1.11-1.27，p <0.001）。他汀类药物的使用与死亡率的改变无关，但与严重COVID-19感染的风险增加18%有关。
There is an urgent need for novel therapeutic strategies for reversing COVID-19-related lung inflammation. Recent evidence has demonstrated that the cholesterol-lowering agents, statins, are associated with reduced mortality in patients with various respiratory infections. We sought to investigate the relationship between statin use and COVID-19 disease severity in hospitalized patients. A retrospective analysis of COVID-19 patients admitted to the Johns Hopkins Medical Institutions between March 1, 2020 and June 30, 2020 was performed. The outcomes of interest were mortality and severe COVID-19 infection, as defined by prolonged hospital stay (≥ 7 days) and/ or invasive mechanical ventilation. Logistic regression, Cox proportional hazards regression and propensity score matching were used to obtain both univariable and multivariable associations between covariates and outcomes in addition to the average treatment effect of statin use. Of the 4,447 patients who met our inclusion criteria, 594 (13.4%) patients were exposed to statins on admission, of which 340 (57.2%) were male. The mean age was higher in statin users compared to non-users [64.9 ± 13.4 vs. 45.5 ± 16.6 years, p <0.001]. The average treatment effect of statin use on COVID-19-related mortality was RR = 1.00 (95% CI: 0.99–1.01, p = 0.928), while its effect on severe COVID-19 infection was RR = 1.18 (95% CI: 1.11–1.27, p <0.001). Statin use was not associated with altered mortality, but with an 18% increased risk of severe COVID-19 infection.
登录
查看更多内容
影响因子：
7.7
作者：
Zamorano Cuervo N;Grandvaux N
通讯作者：
Grandvaux N
影响因子：
6.5
作者：
Bruiners N;Dutta NK;Guerrini V;Salamon H;Yamaguchi KD;Karakousis PC;Gennaro ML
通讯作者：
Gennaro ML
DOI：
10.1080/08998280.2018.1499293
发表时间：
2018-10-01
期刊：
Proceedings (Baylor University. Medical Center)
影响因子：
--
作者：
Henry, Christopher;Zaizafoun, Manaf;White, Heath D
通讯作者：
White, Heath D
影响因子：
3
作者：
Moore, Brian J.;White, Susan;Elixhauser, Anne
通讯作者：
Elixhauser, Anne
影响因子：
4.9
作者：
Gower, TL;Graham, BS
通讯作者：
Graham, BS